Dr. Donald Bers' lab at UC Davis focuses on understanding the critical molecular mechanisms that lead to heart failure and arrhythmias, which are significant health issues worldwide. They investigate the role of proteins like the cardiac ryanodine receptor and CaMKII, using advanced techniques to explore how these proteins function under normal and pathological conditions. The ultimate goal is to develop new therapeutic strategies targeting these molecular mechanisms to improve heart health.

Professor Thomas E Ferrin's lab focuses on creating advanced software tools for visualizing and analyzing complex molecular structures. Their primary program, ChimeraX, allows researchers to interact with detailed biological data, helping to uncover insights about diseases and drug targets. The lab aims to make these powerful tools accessible to scientists worldwide, enhancing our understanding of molecular biology and contributing to improvements in biomedical research.

The lab led by Dr. Zhengqiang Wang at the University of Minnesota focuses on developing new antiviral drugs specifically targeting the monkeypox virus (mpox). The current need for effective treatments arises from a global outbreak and the limitations of existing smallpox medications against this virus. The team employs a multidisciplinary approach, combining various fields to optimize drug candidates and understand their mechanisms of action.

Dr. Arumugaswami's lab focuses on understanding monkeypox virus, particularly how it affects the eyes, leading to serious conditions like keratitis and corneal opacity. They explore both the viral mechanisms that enable the monkeypox virus to evade the immune system and the host responses that occur during infection. The ultimate goal is to find new potential therapies to treat ocular complications caused by this virus.

Dr. James J. Moon's lab focuses on developing innovative treatments for aggressive cancers, particularly head and neck squamous cell carcinoma. The lab explores the use of engineered nanoparticles to activate the STING immune pathway, aiming to improve patient responses to immunotherapy. They are also investigating how to modulate the gut microbiome to enhance cancer treatments, creating formulations that can be administered orally to boost immune responses safely.

Dr. Swati More's research lab focuses on understanding the role of angiotensin-converting enzyme (ACE) in the brain and its implications for opioid signaling. The lab aims to identify small molecules that can selectively inhibit ACE, potentially leading to new treatments for opioid use disorders without the adverse cardiovascular effects. The research involves innovative screening methods and behavioral assessments related to opioid rewards and addiction.

Dr. Stefano Morotti's lab focuses on understanding heart failure with preserved ejection fraction (HFpEF), a condition affecting many, particularly women. The lab combines experimental and computational techniques to investigate how the disease varies among patients and to identify potential new treatments. By studying the cellular mechanisms behind HFpEF, they aim to develop more effective therapies tailored to different patient profiles.

Dr. David D Mott's lab focuses on understanding how the brain regulates emotions, particularly through a neurotransmitter called acetylcholine. The lab investigates the amygdala, a brain region critical for fear and anxiety, and how it communicates with another area, the prefrontal cortex. By exploring these connections at the cellular level, the research aims to uncover mechanisms that could lead to better treatments for anxiety and related disorders.

Dr. Caius Gabriel Radu's lab is focused on creating innovative mRNA vaccines aimed at improving cancer treatment, specifically for pancreatic cancer. The research explores how these vaccines can enhance therapies that involve transferring immune cells to fight tumors. By studying these vaccines in complex mouse models that mimic human immune systems, the lab aims to address challenges in current cancer therapies and develop effective treatments for patients with difficult-to-treat cancers.

Dr. Chintan Dave's lab focuses on understanding how multiple health conditions, known as multimorbidity, affect medication outcomes in older adults. The lab conducts research that aims to identify the best ways to prescribe medications safely and effectively, especially for elderly patients with complex health issues like chronic kidney disease. By analyzing large datasets, the lab seeks to create evidence-based guidelines that can ultimately improve treatment decisions for this vulnerable population.

Dr. Robert Dirksen's lab focuses on understanding tubular aggregate myopathy (TAM), a genetic muscle disease that affects strength and endurance. The team utilizes specially designed mouse models to explore the underlying mechanisms of this disease and to test potential treatments. Their work aims to provide new insights that could ultimately lead to effective therapies for people suffering from TAM.

Dr. Yue Yang's lab focuses on understanding how obesity affects pancreatic beta cells, which are essential for insulin production. They investigate the role of NAD+, a metabolite that supports cell function and survival, and how its depletion contributes to diabetes. By exploring new compounds that boost NAD+ levels, they aim to develop innovative therapies to treat Type 2 Diabetes and restore beta cell function.

The research lab led by Song Li at the University of Pittsburgh focuses on developing novel therapies for metastatic breast and colon cancers. They are working on advanced drug delivery systems using nanoparticles to combine RNA interference with classic chemotherapy, aiming to improve treatment effectiveness and overcome drug resistance in cancer patients. The lab's research has potential implications for enhancing immune responses against tumors.

Dr. Thomas Anchordoquy's research lab at the University of Colorado Denver focuses on improving cancer chemotherapy by developing strategies to minimize the off-target accumulation of drug-containing nanoparticles in healthy tissues. This innovative approach leverages the immune response to enhance drug delivery specifically to tumors while reducing adverse effects. The lab's work is essential in finding ways to make cancer treatments more effective and less toxic for patients.

Dr. Xinxin Ding's lab at the University of Arizona studies the harmful effects of naphthalene, a common pollutant found in smoke and vehicle exhaust, particularly focusing on how it can cause lung damage and cancer. The lab investigates how naphthalene is processed in the body, especially in the liver, and how these processes lead to toxic effects in the lungs. Their work aims to better understand the risk factors associated with exposure to this chemical and to find ways to monitor its effects on human health.

Professor Manuel F. Navedo's lab at UC Davis focuses on understanding the mechanisms behind vascular smooth muscle dysfunction related to diabetes and heart failure. The research particularly investigates how pressure influences calcium channels in blood vessels and how this process can affect blood flow and blood pressure in health and disease. By exploring these mechanisms, the lab aims to identify new potential treatments for vascular complications associated with lifestyle-related diseases.

Dr. Donald Defranco's lab focuses on finding safer treatment options for neonatal lung injury, specifically targeting bronchopulmonary dysplasia (BPD) in premature infants. The lab investigates how a drug called ciclesonide can help prevent lung damage without causing harmful effects on the brain, unlike traditional glucocorticoids. Their research aims to ensure that treatments for neonatal conditions do not compromise brain development during critical early life stages.

Dr. Kendall Nettles' lab at the University of Florida studies how hormones like estrogen and cortisol affect cancer and bodily responses to stress. They are working on developing new therapies for breast cancer that can overcome drug resistance and also on improving synthetic glucocorticoids to minimize side effects like muscle atrophy and insulin resistance. By understanding the molecular mechanisms involved, their goal is to create targeted treatments that are more effective and less harmful.

Dr. Zixu Mao's lab at Emory University focuses on understanding the molecular mechanisms involved in Alzheimer’s and Parkinson’s diseases. The lab investigates how cellular processes, particularly involving exosomes and lysosomes, respond to stress and contribute to neurodegeneration. By studying these processes, the lab aims to uncover new therapeutic targets and improve our understanding of how these devastating diseases progress.

Dr. May Khanna's research lab at the University of Florida focuses on understanding the interactions between TDP-43 and Tau proteins, which are important in Alzheimer's disease and other neurodegenerative disorders. The lab studies how these proteins interact under normal and pathological conditions, and explores potential therapeutic interventions to disrupt harmful interactions. This research could lead to innovative treatments for neurodegenerative diseases.